Arcutis Biotherapeutics, Inc.
ARQTNext catalyst
Roflumilast
Mild to moderate atopic dermatitis in infants aged 3 to 24 months
Get an email about ARQT's next catalysts
Track Arcutis Biotherapeutics (ARQT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ARQT Earnings Report
EPS Est: $0.17 | FQ end Sep/2026 | Call: amc
FDA PDUFA Date ZORYVE (roflumilast) cream 0.05% (standard)
For Mild to moderate atopic dermatitis in infants aged 3 to 24 months. sNDA filing. Extracted from SEC filing: EX-99.1
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
Roflumilast Cream
Atopic Dermatitis Eczema
ARQ-151 Cream or ARQ-151
Atopic Dermatitis Eczema
Roflumilast
Plaque Psoriasis
Topical roflumilast
Chronic Plaque Psoriasis
ARQ-151
Psoriasis
ARQ-151 Active
Atopic Dermatitis Eczema
Roflumilast Foam
Seborrheic Dermatitis
Roflumilast topical foam
Non-segmental Vitiligo
ARQ-252
Chronic Hand Eczema
ARQ-154
Seborrheic Dermatitis
Topical roflumilast foam
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Roflumilast Cream | Phase 3 | Atopic Dermatitis Eczema | - | - |
ARQ-151 Cream or ARQ-151 | Phase 3 | Atopic Dermatitis Eczema | - | - |
Roflumilast | Phase 3 | Plaque Psoriasis | - | - |
Topical roflumilast | Phase 3 | Chronic Plaque Psoriasis | - | - |
ARQ-151 | Phase 3 | Psoriasis | - | - |
ARQ-151 Active | Phase 3 | Atopic Dermatitis Eczema | - | - |
Roflumilast Foam | Phase 3 | Seborrheic Dermatitis | - | - |
Roflumilast topical foam | Phase 2 | Non-segmental Vitiligo | - | - |
ARQ-252 | Phase 2 | Chronic Hand Eczema | - | - |
ARQ-154 | Phase 2 | Seborrheic Dermatitis | - | - |
Topical roflumilast foam | Phase 2 | Hidradenitis Suppurativa | - | - |
Frequently asked questions
What is in Arcutis Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Arcutis Biotherapeutics, Inc.'s (ARQT) pipeline across Phase 3, Phase 2. Its lead program is Roflumilast (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arcutis Biotherapeutics, Inc.'s next FDA catalyst?→
Arcutis Biotherapeutics, Inc.'s (ARQT) next tracked catalyst is a PDUFA date expected Feb 23, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARQT biotech catalysts?→
Add ARQT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arcutis Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.